SpyGlass Pharma, Inc. (SGP)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 43/100 (MEDIUM), 47.2 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 19.36% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability
- SpyGlass Pharma to Participate in Upcoming Investor Conferences
- SpyGlass Pharma Celebrates Grand Opening of New Irvine Headquarters, Positioning Itself for First Product Launch and Custom R&D Space
- SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing
- SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System
- SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
- SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
- SpyGlass Pharma Appoints Shannon Treviño as General Counsel
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- SpyGlass Direct Visualization System: A Cost-Effective Approach Enhancing Nutritional and Immune Recovery in Difficult Bile Duct Stone Management. — Yonsei Med J 2026 Jun PMID 42198857
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for SpyGlass Pharma, Inc..
Full SGP Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.